Can a simple blood test predict infections in CLL and myeloma patients?

NCT ID NCT05844033

Ongoing Knowledge-focused Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is looking for a better way to predict infection risk in people with chronic lymphocytic leukemia (CLL) or multiple myeloma. Researchers will use advanced lab tests on blood samples from 150 participants to find a biomarker that could warn doctors ahead of time. The goal is to personalize care and reduce serious infections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a simple blood test that helps doctors predict which patients are at higher risk for infections, allowing for earlier preventive care.
What could go wrong: This is an observational study, not a treatment trial. The biomarker may not prove accurate enough for routine use, and results may take years to confirm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA MULTIPLE MYELOMA

Contacts and locations

Locations

Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.